An Exploratory Study of Sunitinib (SU) Plus Docetaxel (D) and Trastuzumab (T) for First-Line Therapy of HER2+Advanced Breast Cancer (ABC).

被引：0
作者：
Dirix, L.
Canon, J. L.
Amadori, D.
Villa, E.
Aldrighetti, D.
Machiels, J. P.
Verkh, L.
Bouko, Y.
Kem, K.
Giorgetti, C.
Cardoso, F.
机构：
[1] AZ ST Augustinus, Antwerp, Belgium
[2] Grand Hop Charleroi, Charleroi, Belgium
[3] IRST, Meldola, Italy
[4] San Raffaele, Milan, Italy
[5] Univ Catholique Louvain, B-1200 Brussels, Belgium
[6] Pfizer Oncol, La Jolla, CA USA
[7] Pfizer Oncol, Milan, Italy
[8] Inst Jules Bordet, B-1000 Brussels, Belgium
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：852S / 853S
页数：2
相关论文
共 50 条
[31]   Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer [J].
Farhat, Fadi ;
Kattan, Joseph G. ;
Ghosn, Marwan .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) :1069-1077
[32]   Phase II clinical trial of first-line eribulin plus trastuzumab for advanced or recurrent HER2-positive breast cancer [J].
Sakaguchi, K. ;
Nakatsukasa, K. ;
Taguchi, T. .
ANNALS OF ONCOLOGY, 2018, 29 :99-99
[33]   Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer [J].
Sakaguchi, Koichi ;
Nakatsukasa, Katsuhiko ;
Koyama, Hiroshi ;
Kato, Makoto ;
Sakuyama, Akira ;
Matsuda, Takayuki ;
Tsunoda, Nobuyuki ;
Fujiwara, Ikuya ;
Yamaguchi, Masahide ;
Tanaka, Hiroki ;
Onishi, Kazuyoshi ;
Onishi, Mie ;
Yoshino, Yuji ;
Kikuchi, Takashi ;
Taguchi, Tetsuya .
ANTICANCER RESEARCH, 2018, 38 (07) :4073-4081
[34]   Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer [J].
Najagami, K. ;
Inoue, K. ;
Mizutani, M. ;
Hozumi, Y. ;
Fujiwara, Y. ;
Masuda, N. ;
Tsukamoto, F. ;
Saito, M. ;
Ohashi, Y. ;
Sano, M. ;
Noguchi, S. .
CANCER RESEARCH, 2009, 69 (02) :241S-242S
[35]   Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer [J].
Perez, E. A. ;
Lopez-Vega, J. M. ;
Del Mastro, L. ;
Petit, T. ;
Zamagni, C. ;
Freudensprung, U. ;
Bastiere-Truchot, L. ;
Walker, R. ;
Andersson, M. .
CANCER RESEARCH, 2013, 73
[36]   PH IB/II STUDY OF BKM120 PLUS TRASTUZUMAB (T) IN PATIENTS WITH T-RESISTANT HER2+ADVANCED BREAST CANCER (BC) [J].
Pistilli, B. ;
Urruticoechea, A. ;
Chan, S. ;
Han, H. S. ;
Jerusalem, G. ;
Kong, A. ;
Ru, Q. ;
Ruquet, S. ;
Sternberg, D. W. ;
Saura, C. .
ANNALS OF ONCOLOGY, 2012, 23 :116-116
[37]   Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study [J].
Andersson, Michael ;
Lidbrink, Elisabeth ;
Bjerre, Karsten ;
Wist, Erik ;
Enevoldsen, Kristin ;
Jensen, Anders B. ;
Karlsson, Per ;
Tange, Ulla B. ;
Sorensen, Peter G. ;
Moller, Susanne ;
Bergh, Jonas ;
Langkjer, Sven T. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) :264-271
[38]   Prognostic value of natural killer cell activity for patients with HER2+advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab [J].
Cho, Hyungwoo ;
Ryu, Min-Hee ;
Lee, Hyung Eun ;
Kim, Hyung-Don ;
Kang, Yoon-Koo .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (04) :829-838
[39]   Pooled efficacy analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2: Advanced breast cancer (ABC) [J].
Tripathy, D. ;
Hortobagyi, G. N. ;
Chan, A. ;
Im, S-A. ;
Chia, S. ;
Yardley, D. ;
Esteva, F. J. ;
Hurvitz, S. A. ;
Ridolfi, A. ;
Slamon, D. .
ANNALS OF ONCOLOGY, 2019, 30 :49-+
[40]   Dose finding study of high-dose epirubicin (E) and docetaxel (D) as first-line chemotherapy in advanced breast cancer (ABC) [J].
Pagani, O ;
Sessa, C ;
Martinelli, G ;
Crivellari, D ;
Goldhirsch, A .
EUROPEAN JOURNAL OF CANCER, 1998, 34 :S7-S7
12345